{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T04:53:02Z","timestamp":1781153582814,"version":"3.54.1"},"reference-count":81,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2012,4,1]],"date-time":"2012-04-01T00:00:00Z","timestamp":1333238400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,4,1]]},"abstract":"<jats:title>Learning Objectives:<\/jats:title>\n               <jats:p>After completing this course, the reader will be able to: Identify symptoms of hypophysitis as an infrequent immune related side effect of ipilimumab and other anti-CTLA-4 monoclonal antibodies.Select the appropriate diagnostic and therapeutic work-up for patients suspected of having anti-CTLA-4 monoclonal-induced hypophysitis.<\/jats:p>\n               <jats:p>CME This article is available for continuing medical education credit at CME.TheOncologist.com<\/jats:p>\n               <jats:p>Specific human monoclonal antibodies antagonize cytotoxic T-lymphocyte antigen 4 (anti\u2013CTLA-4 mAbs), a negative regulator of the immune system, inducing unrestrained T-cell activation. In patients with advanced or metastatic melanoma, one of these agents, ipilimumab, produced considerable disease control rates and, for the first time, a clear improvement in overall survival outcomes. However, accumulating clinical experience with anti\u2013CTLA-4 mAbs identified a novel syndrome of autoimmune and autoinflammatory side effects, designated as \u201cimmune-related adverse events,\u201d including mainly rash, colitis, and hepatitis. Autoimmune hypophysitis has emerged as a distinctive side effect induced by anti\u2013CTLA-4 mAbs. This condition may be life threatening because of adrenal insufficiency if not promptly recognized, but it may easily be diagnosed and treated if clinically suspected. Hypopituitarism caused by these agents is rarely reversible and prolonged or life-long substitutive hormonal treatment is often required. The precise mechanism of injury to the pituitary triggered by anti\u2013CTLA-4 mAbs is yet to be fully elucidated.<\/jats:p>","DOI":"10.1634\/theoncologist.2011-0404","type":"journal-article","created":{"date-parts":[[2012,4,4]],"date-time":"2012-04-04T06:08:16Z","timestamp":1333519696000},"page":"525-535","source":"Crossref","is-referenced-by-count":71,"title":["Hypophysitis Induced by Monoclonal Antibodies to Cytotoxic T Lymphocyte Antigen 4: Challenges from a New Cause of a Rare Disease"],"prefix":"10.1093","volume":"17","author":[{"given":"Francesco","family":"Torino","sequence":"first","affiliation":[{"name":"a Department of Internal Medicine, University of Rome \u201cTor Vergata,\u201d Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnese","family":"Barnabei","sequence":"additional","affiliation":[{"name":"c Endocrinology Unit, National Institute of Cancer \u201cRegina Elena,\u201d Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liana","family":"De Vecchis","sequence":"additional","affiliation":[{"name":"b Department of Neuroscience, University of Rome \u201cTor Vergata,\u201d Rome, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Salvatori","sequence":"additional","affiliation":[{"name":"d Pituitary Center, Division of Endocrinology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore M.","family":"Corsello","sequence":"additional","affiliation":[{"name":"e Endocrinology Unit, Universit\u00e0 Cattolica, Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2012,4,3]]},"reference":[{"key":"2021122308131165500_B1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1053\/j.seminoncol.2010.09.010","article-title":"Clinical development of the anti-CTLA-4 antibody tremelimumab","volume":"37","author":"Ribas","year":"2010","journal-title":"Semin Oncol"},{"issue":"15 suppl","key":"2021122308131165500_B2","first-page":"LBA90111","article-title":"Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or dacarbazine [DTIC]) in patients with advanced melanoma","volume":"26","author":"Ribas","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B3","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1003466","article-title":"Improved survival with ipilimumab in patients with metastatic melanoma","volume":"363","author":"Hodi","year":"2010","journal-title":"N Engl J Med"},{"key":"2021122308131165500_B4","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"key":"2021122308131165500_B5","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1097\/CJI.0b013e318156e47e","article-title":"Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis","volume":"30","author":"Yang","year":"2007","journal-title":"J Immunother"},{"key":"2021122308131165500_B6","doi-asserted-by":"crossref","DOI":"10.1016\/j.juro.2010.02.1055","volume-title":"A randomized phase II study of ipilimumab with androgen ablation compared with androgen ablation alone in patients with advanced prostate cancer [abstract 168]","author":"Tollefson","year":"2010"},{"key":"2021122308131165500_B7","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1053\/j.seminoncol.2010.09.009","article-title":"Anti-CTLA-4 antibody adjuvant therapy in melanoma","volume":"37","author":"Eggermont","year":"2010","journal-title":"Semin Oncol"},{"key":"2021122308131165500_B8","doi-asserted-by":"crossref","first-page":"6043","DOI":"10.1200\/JCO.2005.06.205","article-title":"Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4","volume":"23","author":"Attia","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B9","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1200\/JCO.2010.28.3994","article-title":"Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer","volume":"28","author":"Chung","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B10","doi-asserted-by":"crossref","first-page":"8968","DOI":"10.1200\/JCO.2005.01.109","article-title":"Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206","volume":"23","author":"Ribas","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B11","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1200\/JCO.2005.01.128","article-title":"Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma","volume":"23","author":"Sanderson","year":"2005","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B12","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/j.seminoncol.2010.09.004","article-title":"Ipilimumab: Unleashing the power of the immune system through CTLA-4 blockade","volume":"37","author":"Boasberg","year":"2010","journal-title":"Semin Oncol"},{"key":"2021122308131165500_B13","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1053\/j.seminoncol.2010.09.003","article-title":"Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: Identification of clinical and biological response patterns, immune-related adverse events, and their management","volume":"37","author":"Kaehler","year":"2010","journal-title":"Semin Oncol"},{"issue":"15 suppl","key":"2021122308131165500_B14","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1200\/jco.2008.26.15_suppl.3040","article-title":"Safety of tremelimumab (CP-675,206) in patients (pts) with advanced cancer","volume":"26","author":"Wallis","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/01.cji.0000208259.73167.58","article-title":"Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma","volume":"29","author":"Maker","year":"2006","journal-title":"J Immunother"},{"key":"2021122308131165500_B16","volume-title":"Analysis of the onset and resolution of immune-related adverse events during treatment with ipilimumab in patients with metastatic melanoma [abstract O-015]","author":"Lebbe","year":"2008"},{"key":"2021122308131165500_B17","first-page":"9","article-title":"Ipilimumab efficacy and safety in patients with advanced melanoma: A retrospective analysis of HLA subtype from four trials","volume":"10","author":"Wolchok","year":"2010","journal-title":"Cancer Immun"},{"key":"2021122308131165500_B18","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1078-0432.CCR-09-2033","article-title":"Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma","volume":"16","author":"Kirkwood","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2021122308131165500_B19","doi-asserted-by":"crossref","first-page":"2283","DOI":"10.1200\/JCO.2005.04.5716","article-title":"Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4","volume":"24","author":"Beck","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B20","doi-asserted-by":"crossref","first-page":"6681","DOI":"10.1158\/1078-0432.CCR-07-0187","article-title":"Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade","volume":"13","author":"Downey","year":"2007","journal-title":"Clin Cancer Res"},{"key":"2021122308131165500_B21","doi-asserted-by":"crossref","first-page":"5950","DOI":"10.1200\/JCO.2008.16.1927","article-title":"Phase I\/II study of ipilimumab for patients with metastatic melanoma","volume":"26","author":"Weber","year":"2008","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B22","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/cncr.24951","article-title":"Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: Lymphocyte count after 2 doses correlates with survival","volume":"116","author":"Ku","year":"2010","journal-title":"Cancer"},{"key":"2021122308131165500_B23","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1053\/j.seminoncol.2010.09.001","article-title":"Anti-CTLA-4 antibody therapy: Immune monitoring during clinical development of a novel immunotherapy","volume":"37","author":"Callahan","year":"2010","journal-title":"Semin Oncol"},{"key":"2021122308131165500_B24","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/CJI.0b013e3181dcd260","article-title":"Current experience with CTLA4-blocking monoclonal antibodies for the treatment of solid tumors","volume":"33","author":"Agarwala","year":"2010","journal-title":"J Immunother"},{"key":"2021122308131165500_B25","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1016\/S0140-6736(07)60673-4","volume":"369","author":"Schneider","year":"2007","journal-title":"Hypopituitarism Lancet"},{"key":"2021122308131165500_B26","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1210\/er.2004-0011","article-title":"Autoimmune hypophysitis","volume":"26","author":"Caturegli","year":"2005","journal-title":"Endocr Rev"},{"key":"2021122308131165500_B27","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1210\/jc.2010-2970","article-title":"IgG4-related hypophysitis: A new addition to the hypophysitis spectrum","volume":"96","author":"Leporati","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122308131165500_B28","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.autrev.2008.04.016","article-title":"Pituitary autoimmunity: 30 years later","volume":"7","author":"Caturegli","year":"2008","journal-title":"Autoimm Rev"},{"issue":"suppl 5","key":"2021122308131165500_B29","first-page":"145","article-title":"Lymphocytic hypophysitis","volume":"68","author":"Molitch","year":"2007","journal-title":"Horm Res"},{"key":"2021122308131165500_B30","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1097\/01.pas.0000149707.12335.8e","article-title":"Immunopathology of primary hypophysitis: Implications for pathogenesis","volume":"29","author":"Gutenberg","year":"2005","journal-title":"Am J Surg Pathol"},{"key":"2021122308131165500_B31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1530\/eje.0.1490363","article-title":"Lymphocytic hypophysitis: A rare or underestimated disease?","volume":"149","author":"Bellastella","year":"2003","journal-title":"Eur J Endocrinol"},{"key":"2021122308131165500_B32","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-011-0338-8","article-title":"Growth hormone and proopiomelanocortin are targeted by autoantibodies in a patient with biopsy-proven IgG4-related hypophysitis","author":"Landek-Salgado","year":"2011","journal-title":"Pituitary"},{"key":"2021122308131165500_B33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/01.rmr.0000224686.21748.ea","article-title":"Inflammatory and infectious processes involving the pituitary gland","volume":"16","author":"Lury","year":"2005","journal-title":"Top Magn Reson Imaging"},{"key":"2021122308131165500_B34","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s11102-006-6598-z","article-title":"Lymphocytic hypophysitis: Disease spectrum and approach to diagnosis and therapy","volume":"9","author":"Rivera","year":"2006","journal-title":"Pituitary"},{"key":"2021122308131165500_B35","first-page":"2302","article-title":"Clinical case seminar: Lymphocytic hypophysitis: Clinicopathological findings","volume":"80","author":"Thodou","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122308131165500_B36","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/S0140-6736(75)90004-5","article-title":"Autoantibodies to prolactin-secreting cells of human pituitary","volume":"2","author":"Bottazzo","year":"1975","journal-title":"Lancet"},{"key":"2021122308131165500_B37","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/02688698809001013","article-title":"Lymphocytic adenohypophysitis. Report of a case with demonstration of spontaneous tumour regression and a review of the literature","volume":"2","author":"Castle","year":"1988","journal-title":"Br J Neurosurg"},{"key":"2021122308131165500_B38","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/07435808209045760","article-title":"Evidence for cellular mediated immunity in an animal model of autoimmune pituitary disease","volume":"9","author":"Klein","year":"1982","journal-title":"Endocr Res Commun"},{"key":"2021122308131165500_B39","doi-asserted-by":"publisher","first-page":"2182","DOI":"10.3791\/2182","article-title":"Induction of experimental autoimmune hypophysitis in SJL mice","volume":"17","author":"Landek-Salgado","year":"2010","journal-title":"J Vis Exp"},{"key":"2021122308131165500_B40","doi-asserted-by":"crossref","first-page":"4190","DOI":"10.1210\/en.2011-1004","article-title":"From pituitary expansion to empty sella: Disease progression in a mouse model of autoimmune hypophysitis","volume":"152","author":"Lupi","year":"2011","journal-title":"Endocrinology"},{"key":"2021122308131165500_B41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJM199309023291002","article-title":"Lymphocytic infundibuloneurohypophysitis as a cause of central diabetes insipidus","volume":"329","author":"Imura","year":"1993","journal-title":"N Engl J Med"},{"key":"2021122308131165500_B42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10014-008-0234-8","article-title":"Lymphocytic infundibulo-neurohypophysitis and infundibulo-panhypophysitis regarded as lymphocytic hypophysitis variant","volume":"25","author":"Abe","year":"2008","journal-title":"Brain Tumor Pathol"},{"key":"2021122308131165500_B43","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1210\/jcem-70-5-1391","article-title":"Isolated adrenocorticotropin deficiency associated with an autoantibody to a corticotroph antigen that is not adrenocorticotropin or other proopiomelanocortin-derived peptides","volume":"70","author":"Sauter","year":"1990","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122308131165500_B44","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1507\/endocrj.44.453","article-title":"Simultaneously found transient hypothyroidism due to Hashimoto's thyroiditis, autoimmune hepatitis and isolated ACTH deficiency after cessation of glucocorticoid administration","volume":"44","author":"Nagai","year":"1997","journal-title":"Endocr J"},{"key":"2021122308131165500_B45","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJM198506133122402","article-title":"Isolated gonadotrope failure in the polyglandular autoimmune syndrome","volume":"312","author":"Barkan","year":"1985","journal-title":"N Engl J Med"},{"key":"2021122308131165500_B46","first-page":"439","article-title":"Hypophysitis: Endocrinologic and dynamic MR findings","volume":"19","author":"Sato","year":"1998","journal-title":"AJNR Am J Neuroradiol"},{"key":"2021122308131165500_B47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1111\/j.1365-2265.1995.tb01881.x","article-title":"Lymphocytic adenohypophysitis: Magnetic resonance imaging features of two new cases and a review of the literature","volume":"42","author":"Powrie","year":"1995","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2021122308131165500_B48","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.3174\/ajnr.A1714","article-title":"A radiologic score to distinguish autoimmune hypophysitis from nonsecreting pituitary adenoma preoperatively","volume":"30","author":"Gutenberg","year":"2009","journal-title":"AJNR Am J Neuroradiol"},{"key":"2021122308131165500_B49","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1210\/jc.2010-0551","article-title":"Predictive role of the immunostaining pattern of immunofluorescence and the titers of antipituitary antibodies at presentation for the occurrence of autoimmune hypopituitarism in patients with autoimmune polyendocrine syndromes over a five-year follow-up","volume":"95","author":"Bellastella","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122308131165500_B50","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1007\/s11102-009-0193-z","article-title":"Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: Serious immune related adverse events across a spectrum of cancer subtypes","volume":"13","author":"Dillard","year":"2010","journal-title":"Pituitary"},{"key":"2021122308131165500_B51","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1053\/j.seminoncol.2010.09.007","article-title":"The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications","volume":"37","author":"Di Giacomo","year":"2010","journal-title":"Semin Oncol"},{"key":"2021122308131165500_B52","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1245\/ASO.2005.03.536","article-title":"Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte\u2013associated antigen 4 blockade and interleukin 2: A phase I\/II study","volume":"12","author":"Maker","year":"2005","journal-title":"Ann Surg Oncol"},{"key":"2021122308131165500_B53","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1097\/01.cji.0000178913.41256.06","article-title":"Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer","volume":"28","author":"Blansfield","year":"2005","journal-title":"J Immunother"},{"issue":"15 suppl","key":"2021122308131165500_B54","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1200\/jco.2010.28.15_suppl.7531","article-title":"Phase II trial of ipilimumab (IPI) and paclitaxel\/carboplatin (P\/C) in first-line stage IIIb\/IV non-small cell lung cancer (NSCLC)","volume":"28","author":"Lynch","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B55","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s00262-010-0958-2","article-title":"Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)","volume":"60","author":"Di Giacomo","year":"2011","journal-title":"Cancer Immunol Immunother"},{"issue":"suppl 4","key":"2021122308131165500_B56","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/theoncologist.13-S4-16","article-title":"Overcoming immunologic tolerance to melanoma: Targeting CTLA-4 with ipilimumab (MDX-010)","volume":"13","author":"Weber","year":"2008","journal-title":"The Oncologist"},{"key":"2021122308131165500_B57","doi-asserted-by":"crossref","first-page":"5591","DOI":"10.1158\/1078-0432.CCR-09-1024","article-title":"A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma","volume":"15","author":"Weber","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308131165500_B58","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1210\/edrv.19.2.0328","article-title":"The endocrine effects of nonhormonal antineoplastic therapy","volume":"19","author":"Yeung","year":"1998","journal-title":"Endocr Rev"},{"key":"2021122308131165500_B59","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s11102-008-0088-4","article-title":"Hypopituitarism following radiotherapy","volume":"12","author":"Darzy","year":"2009","journal-title":"Pituitary"},{"key":"2021122308131165500_B60","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/S0140-6736(95)90950-8","article-title":"Reversible hypopituitarism after interferon\u03b1 therapy","volume":"345","author":"Sakane","year":"1995","journal-title":"Lancet"},{"key":"2021122308131165500_B61","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S0002-9343(02)01323-2","article-title":"Interferon-induced hypopituitarism","volume":"114","author":"Concha","year":"2003","journal-title":"Am J Med"},{"key":"2021122308131165500_B62","first-page":"93","article-title":"Panhypopituitarism in association with interferon-alpha treatment","volume":"45","author":"Chan","year":"2004","journal-title":"Singapore Med J"},{"key":"2021122308131165500_B63","doi-asserted-by":"crossref","first-page":"169","DOI":"10.4158\/EP.13.2.169","article-title":"Granulomatous adenohypophysitis after interferon and ribavirin therapy","volume":"13","author":"Tebben","year":"2007","journal-title":"Endocr Pract"},{"key":"2021122308131165500_B64","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1097\/00042737-200606000-00019","article-title":"Central hypothyroidism and hypophysitis during treatment of chronic hepatitis C with pegylated interferon alpha and ribavirin","volume":"18","author":"Ridruejo","year":"2006","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2021122308131165500_B65","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/jnci\/djr373","article-title":"Thyroid dysfunction from antineoplastic agents","volume":"103","author":"Hamnvik","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"2021122308131165500_B66","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1158\/1078-0432.CCR-08-2424","article-title":"Melan-A-specific cytotoxic T cells are associated with tumor regression and autoimmunity following treatment with anti-CTLA-4","volume":"15","author":"Klein","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308131165500_B67","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1111\/j.1365-2249.2008.03828.x","article-title":"T regulatory cells distinguish two types of primary hypophysitis","volume":"155","author":"Mirocha","year":"2009","journal-title":"Clin Exp Immunol"},{"key":"2021122308131165500_B68","doi-asserted-by":"crossref","first-page":"E1466","DOI":"10.1210\/jc.2011-0228","article-title":"Significance of prediagnostic thyroid antibodies in women with autoimmune thyroid disease","volume":"96","author":"Hutfless","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"2021122308131165500_B69","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1158\/1078-0432.CCR-09-2870","article-title":"Modulation of lymphocyte regulation for cancer therapy: A phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma","volume":"16","author":"Ralph","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"18 suppl","key":"2021122308131165500_B70","doi-asserted-by":"crossref","first-page":"2508","DOI":"10.1200\/jco.2006.24.18_suppl.2508","article-title":"A phase I trial of combination immunotherapy with CTLA-4 blockade and GM-CSF in hormone-refractory prostate cancer","volume":"24","author":"Fong","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B71","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1158\/1078-0432.CCR-06-2318","article-title":"A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer","volume":"13","author":"Small","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"18 suppl","key":"2021122308131165500_B72","doi-asserted-by":"crossref","first-page":"2510","DOI":"10.1200\/jco.2006.24.18_suppl.2510","article-title":"Phase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multi-peptide vaccine for resected stages IIIC and IV melanoma","volume":"24","author":"Weber","year":"2006","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B73","volume-title":"Expanded phase I combination trial of GVAX immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHPRC) [abstract 5146]","author":"Gerritsen","year":"2008"},{"key":"2021122308131165500_B74","doi-asserted-by":"crossref","first-page":"6446","DOI":"10.1158\/1078-0432.CCR-09-1339","article-title":"Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma","volume":"15","author":"Ansell","year":"2009","journal-title":"Clin Cancer Res"},{"key":"2021122308131165500_B75","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s10637-009-9376-8","article-title":"A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-na\u00efve patients with advanced melanoma","volume":"29","author":"Hersh","year":"2011","journal-title":"Invest New Drugs"},{"key":"2021122308131165500_B76","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/S1470-2045(09)70334-1","article-title":"Ipilimumab monotherapy in patients with pretreated advanced melanoma: A randomised, double-blind, multicentre, phase 2, dose-ranging study","volume":"11","author":"Wolchok","year":"2010","journal-title":"Lancet Oncol"},{"issue":"15 suppl","key":"2021122308131165500_B77","doi-asserted-by":"crossref","first-page":"8511","DOI":"10.1200\/jco.2011.29.15_suppl.8511","article-title":"A phase I trial of ipilimumab plus bevacizumab in patients with unresectable stage III or stage IV melanoma","volume":"29","author":"Hodi","year":"2011","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B78","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1093\/annonc\/mdq013","article-title":"Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: A multicenter single-arm phase II study","volume":"21","author":"O'Day","year":"2010","journal-title":"Ann Oncol"},{"key":"2021122308131165500_B79","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1200\/JCO.2008.19.2435","article-title":"Phase I\/II trial of tremelimumab in patients with metastatic melanoma","volume":"27","author":"Camacho","year":"2009","journal-title":"J Clin Oncol"},{"key":"2021122308131165500_B80","doi-asserted-by":"crossref","first-page":"8372","DOI":"10.1073\/pnas.1533209100","article-title":"Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma","volume":"100","author":"Phan","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2021122308131165500_B81","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1097\/CJI.0b013e3181eec14c","article-title":"Phase 2 trial of single agent ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma","volume":"33","author":"Royal","year":"2010","journal-title":"J Immunother"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/pdf\/10.1634\/theoncologist.2011-0404","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/pericles-gcp.literatumonline.com\/doi\/full-xml\/10.1634\/theoncologist.2011-0404","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/4\/525\/41858369\/oncolo_17_4_525.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/17\/4\/525\/41858369\/oncolo_17_4_525.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,23]],"date-time":"2021-12-23T20:13:47Z","timestamp":1640290427000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/17\/4\/525\/6445228"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,1]]},"references-count":81,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2012,4,3]]},"published-print":{"date-parts":[[2012,4,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2011-0404","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2012,4,1]]},"published":{"date-parts":[[2012,4,1]]}}}